DGAP-News: Apricus Biosciences CEO to Present at Sachs Annual Biotech in Europe Investor Forum
(firmenpresse) - Apricus Biosciences, Inc.
25.09.2012 15:58
---------------------------------------------------------------------------
SAN DIEGO, 2012-09-25 15:58 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
(http://www.apricusbio.com) announced today that Bassam Damaj, Ph.D., President
and Chief Executive Officer, will present at the Sachs 2012 Biotech in Europe
Investor Forum, being held at the Hilton Zurich Airport Hotel, Switzerland.
Apricus Biosciences' presentation will take place on Monday, October 1st at
9:00 a.m. Central European Time.
Dr. Damaj will be giving a corporate update on the Company's licensing efforts
including its recent Vitaros(r) licensing transaction with Takeda for the United
Kingdom and the ongoing efforts for the rest of Europe and Latin America, as
well as a regulatory status update for MycoVa(tm) and Femprox(r).
About Apricus Biosciences, Inc.
Apricus Bio (Nasdaq:APRI) is a pharmaceutical company that develops and markets
innovative treatments that help large patient populations across numerous,
high-demand therapeutic classes. The Company has four approved products and has
developed a strong pipeline of multiple late-stage product opportunities. With
commercial operations in both the U.S. and Europe (France), Apricus Bio
generates revenues and growth from sales of its commercial products and by
out-licensing, in certain territories, its pipeline products and NexACT(r)
technology.
Apricus Bio's growth strategy is to acquire, develop, and commercialize new
products through strategic partnerships. The Company currently has commercial
partnerships with multiple large pharmaceutical companies including Novartis,
Abbot Laboratories, Takeda, Sandoz, Warner Chilcott and Bracco, and co-promotes
multiple products in France.
Apricus Biosciences is headquartered in San Diego, CA and is publicly traded on
the NASDAQ under the ticker symbol APRI.
For further information on Apricus Bio, visit http://www.apricusbio.com, and
for information on its subsidiary please visit http://www.nexmedusa.com. You
can also receive information at http://twitter.com/apricusbio.
Apricus Bio's Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with
the exception of the historical information contained in this release, the
matters described herein contain forward-looking statements that involve risks
and uncertainties that may individually or mutually impact the matters herein
described for a variety of reasons that are outside the control of the Company,
including, but not limited to, its ability to further develop its products and
product candidates, to have its products and product candidates such as
Femprox(r) and MycoVa(tm) receive patent protection and be approved by relevant
regulatory authorities, to successfully commercialize such products as
Vitaros(r), Femprox(r), MycoVa(tm), Totect(r) , Granisol(r) , Aquoral(tm) and NitroMist(tm) and
NexACT(r) product candidates and drug delivery technology and to achieve its
development, commercialization and financial goals. Readers are cautioned not
to place undue reliance on these forward-looking statements as actual results
could differ materially from the forward-looking statements contained herein.
Readers are urged to read the risk factors set forth in the Company's most
recentannual report on Form 10-K, subsequent quarterly reports filed on Form
10-Q and other filings made with the SEC. Copies of these reports are available
from the SEC's website or without charge from the Company.
CONTACT: Apricus Bio Investor Relations:
David Pitts
Argot Partners
212-600-1902
david(at)argotpartners.com
News Source: NASDAQ OMX
25.09.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Apricus Biosciences, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901429525
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 25.09.2012 - 15:58 Uhr
Sprache: Deutsch
News-ID 186586
Anzahl Zeichen: 4020
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 253 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Apricus Biosciences CEO to Present at Sachs Annual Biotech in Europe Investor Forum"
steht unter der journalistisch-redaktionellen Verantwortung von
Apricus Biosciences, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
